NYSE:HLN - US4055521003 - ADR
The current stock price of HLN is 9.63 USD. In the past month the price decreased by -1.83%. In the past year, price decreased by -5.4%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 45.57 | 696.62B | ||
JNJ | JOHNSON & JOHNSON | 17.65 | 425.05B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.03 | 248.19B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.15 | 245.90B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.31 | 245.16B | ||
MRK | MERCK & CO. INC. | 11.04 | 212.29B | ||
PFE | PFIZER INC | 7.35 | 141.68B | ||
SNY | SANOFI-ADR | 11.33 | 122.68B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.09B | ||
GSK | GSK PLC-SPON ADR | 8.79 | 80.29B | ||
ZTS | ZOETIS INC | 24.89 | 68.60B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.6 | 46.99B |
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The firm's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The firm's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
HALEON PLC-ADR
Building 5, First Floor, The Heights
Weybridge SURREY GB
Employees: 24561
Phone: 441932822000
The current stock price of HLN is 9.63 USD. The price decreased by -0.52% in the last trading session.
The exchange symbol of HALEON PLC-ADR is HLN and it is listed on the New York Stock Exchange, Inc. exchange.
HLN stock is listed on the New York Stock Exchange, Inc. exchange.
26 analysts have analysed HLN and the average price target is 11.6 USD. This implies a price increase of 20.47% is expected in the next year compared to the current price of 9.63. Check the HALEON PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HALEON PLC-ADR (HLN) has a market capitalization of 43.20B USD. This makes HLN a Large Cap stock.
HALEON PLC-ADR (HLN) currently has 24561 employees.
HALEON PLC-ADR (HLN) has a support level at 9.61 and a resistance level at 9.65. Check the full technical report for a detailed analysis of HLN support and resistance levels.
The Revenue of HALEON PLC-ADR (HLN) is expected to decline by -1.45% in the next year. Check the estimates tab for more information on the HLN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HALEON PLC-ADR (HLN) has a dividend yield of 1.86%. The yearly dividend amount is currently 0.17. Check the full fundamental report for a detailed analysis of HLN dividend history, reliability and sustainability.
HALEON PLC-ADR (HLN) will report earnings on 2025-10-30.
The PE ratio for HALEON PLC-ADR (HLN) is 19.65. This is based on the reported non-GAAP earnings per share of 0.49 and the current share price of 9.63 USD. Check the full fundamental report for a full analysis of the valuation metrics for HLN.
The outstanding short interest for HALEON PLC-ADR (HLN) is 0.39% of its float. Check the ownership tab for more information on the HLN short interest.
ChartMill assigns a fundamental rating of 5 / 10 to HLN. While HLN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months HLN reported a non-GAAP Earnings per Share(EPS) of 0.49. The EPS increased by 6.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 12.84% | ||
ROA | 4.2% | ||
ROE | 8.92% | ||
Debt/Equity | 0.53 |
26 analysts have analysed HLN and the average price target is 11.6 USD. This implies a price increase of 20.47% is expected in the next year compared to the current price of 9.63.
For the next year, analysts expect an EPS growth of 5.64% and a revenue growth -1.45% for HLN